Mohammed T. Abou-Saleh

SINGLE-PHOTON EMISSION COMPUTERIZED TOMOGRAPHY 367general use in receptor studies is likely to continue and mayfurther extend the role of SPECT.REFERENCES1. Kety S, Schmidt C. The nitrous oxide method for quantitativedetermination of cerebral blood flow in man: theory, procedure, andnormal values. J Clin Invest 1948; 27: 475–83.2. Lassen N, Ingvar D. Regional cerebral blood flow measurement inman: a review. Arch Neurol 1963; 9: 615–22.3. Holman B, Gibson R, Hill T et al. Muscarinic acetylcholine receptorsin Alzheimer’s disease: in vivo imaging with iodine 123-labelled 3-quinuclidinyl-4-iodobenzilate and emission tomography. J Am MedAss 1985; 254: 3063–6.4. Devous M. Imaging brain function by single-photon emissioncomputer tomography. In Andreasen N, ed., Brain Imaging:Applications in Psychiatry. Washington, DC: American PsychiatricPress, 147–234.5. Fox P, Raichle M, Mintum M et al. Nonoxidative glucoseconsumption during focal physiological neural activity. Science1988; 241: 462–4.6. Hoyer S. The abnormally aged brain. Its blood flow and oxidativemetabolism. A review—part 11. Arch Gerontol Geriatr 1982; 1: 195–207.7. Bonte F, Ross E, Chehabi H et al. SPECT study of regional cerebralblood flow in Alzheimer’s disease. J Comp Assist Tomogr 1986; 10:579–83.8. Sharp P, Gemmell H, Cherryman G et al. Application of iodine-123-labelled isopropylamphetamine imaging to the study of dementia. JNucl Med 1986; 27: 761–8.9. Ebmeier K, Besson J, Crawford J et al. Nuclear magnetic resonanceimaging and single photon emission tomography with radio-iodinelabelled compounds in the diagnosis of dementia. Acta PsychiatScand 1987; 75: 549–56.10. Gemmell H, Sharp P, Besson J et al. Differential diagnosis indementia using the cerebral blood flow agent 99m Tc-HMPAO: aSPECT study. J Cerebr Blood Flow Metab 1987; 11: 398–402.11. Neary D, Snowden J, Shields R et al. Single photon emissiontomography using 99m Tc-HMPAO in the investigation of dementia. JNeurol Neurosurg Psychiat 1987; 50: 1101–9.12. Pearson R, Powell T. The neuroanatomy of Alzheimer’s disease. RevNeurosci 1989; 2: 101–22.13. Kushner M, Tobin M, Alavi A et al. Cerebellar glucose consumptionin normal and pathologic states using fluorine-FDG and PET. J NuclMed 1987; 28: 1667–70.14. Pickutt NA, Dierckx RA, Dobbeleir A, Audenaert K, Van Laere K,Vervaet A, De Deyn PP. Validation of the cerebellum as a referenceregion for SPECT quantification in patients suffering from dementiaof the Alzheimer type. Psychiatry Res 1999; 90: 103–12.15. Montaldi D, Brooks D, McColl J et al. Measurements of regionalcerebral blood flow and cognitive performance in Alzheimer’s disease.J Neurol Neurosurg Psychiat 1990; 53: 33–8.16. Burns A, Philpot A, Costa D et al. The investigation of Alzheimer’sdisease with single photon emission tomography. J Neurol NeurosurgPsychiat 1989; 52: 248–53.17. Hunter R, McLuskie R, Wyper D et al. The pattern of functionrelatedregional cerebral blood flow investigated by single photonemission tomography with 99m Tc-HMPAO in patients with presenileAlzheimer’s disease and Korsakoff’s psychosis. Psychol Med 1989; 19:847–55.18. Goldenberg G, Podreka I, Suess E et al. The cerebral localisation ofneuropsychological impairment in Alzheimer’s disease: a SPECTstudy. J Neurol 1989; 236: 131–8.19. Geaney D, Soper N, Shepstone B et al. Effect of central cholinergicstimulation on regional cerebral blood flow in Alzheimer disease.Lancet 1990; 335: 1484–7.20. Galynker II, Dutta E, Vilkas N, Ongseng F, Finestone H, GallagjherR, Serseni D, Rosenthal RN. Hypofrontality and negative symptomsin patients with dementia of Alzheimer type. NeuropsychiatryNeuropsychol Behav Neurol 2000; 13: 53–9.21. Staff RT, Shanks MF, Macintosh L, Pestell SJ, Gemmell HG,Venneri A. Delusions in Alzheimer’s disease: spet evidence of righthemispheric dysfunction. Cortex 1999; 35: 549–60.22. Sultzer DL. Behavioural Syndrome in Dementia: NeuroimagingInsights. Semin Clin Neuropsychiatry 1996; 1: 261–71.23. Dormehl IC, Jordaan B, Oliver DW, Croft S. SPECT monitoringof improved cerebral blood flow during long-term treatmentof elderly patients with nootropic drugs. Clin Nucl Med 1999; 24:39–34.24. Staff RT, Gemmell GH, Shanks MF, Murray AD, Venneri A.Changes in the Rcbf images of patients with Alzheimer’sdisease receiving Donepezil therapy. Nucl Med Commun 2000; 21:37–41.25. Defebvre LJ, Leduc V, Duhamel A, Lecouffe P, Pasquier F, Lamy-Lhullier C, Steinling M, Destee A. Technetium HMPAO SPECTstudy in dementia with Lewy bodies, Alzheimer’s disease andidiopathic Parkinson’s disease. J Nucl Med 1999; 40: 956–62.26. Walker Z, Costa DC, Ince P, McKeith IG, Katona CL. In-vivodemonstration of dopaminergic degeneration in dementia with Lewybodies. Lancet 1999; 354: 646–7.27. San Pedro EC, Deutsch G, Liu HG, Mountz JM. Frontotemporaldecreases in Rcbf correlate with degree of dysnomia in primaryprogressive aphasia. J Nucl Med 2000; 41: 228–33.28. Miller BL, Geerhart R. Neuroimaging in the diagnosis offrontotemporal dementia. Dement Geriaty Cogn Disord 1999; 10Suppl 1: 71–4.29. Charpentier P, Laveny I, Defebvre L, Durhamel A, Lecouffe P,Pasquier F, Steinling M. Alzheimer’s disease and frontotemporaldementia are differentiated by discriminant analysis applied to (99m)Tc HMPAO SPECT data. J Neurol Neurosurg Psychiatry 2000; 69:661–3.30. Perani D, Di Piero V, Vallar G et al. Technetium-99m-HMPAO-SPECT study of regional cerebral perfusion in early Alzheimer’sdisease. J Nucl Med 1988; 29: 1507–14.31. Burns A, Tune L, Steele C et al. Positron emission tomography indementia: a clinical review. Int J Geriat Psychiat 1989; 4: 67–72.32. Battistin L, Pizzolato G, Dam M et al. Single photon emissioncomputed tomography studies with 99m Tc-hexamethylpropyleneamineoxime in dementia: effects of acute administration of L-acetylcarnitine. Eur Neurol 1989; 29: 261–5.33. Podreka I, Suess E, Goldenberg G et al. Initial experience withtechnetium-99m HM-PAO brain SPECT. J Nucl Med 1987; 28:1657–66.34. Upadhyaya AK, Abou-Saleh MT, Wilson K et al. A study ofdepression in old age using single-photon emission computerisedtomography. Br J Psychiat 1990; 157(suppl 9): 76–81.35. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction ofhistologically confirmed Alzheimer’s disease and the differentialdiagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-Rcriteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobedementias. Oxford Project to Investigate Memory and Ageing. IntPsychogeriatr 1998; 10: 271–302.36. Shih WJ, Ashford JW, Coupal JJ, Ryo YU, Stipp V, Magoun SL,Gross K. Consecutive brain SPECT surface three-dimensionaldisplays show progression of cerebral cortical abnormalities inAlzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 1999; 249:190–6.37. Muller H, Moller HJ, Stippel A, Fric M, Grunswald F, Laux G,Klemm E, Biersack HJ. SPECT patterns in probable Alzheimer’sdisease. Eur Arch Psychiatry Clin Neurosci 1999; 249: 190–6.38. Duara R, Barker W, Luis CA. Frontotemporal dementia andAlzheimer’s disease: differential diagnosis. Dement Geriatr Disord1999; 10 Suppl 1: 37–42.39. Smith F, Besson J, Gemmell H et al. The use of technetium-99m-HMPAO in the assessment of patients with dementia and otherneuropsychiatric conditions. J Cerebr Blood Flow Metab 1988; 8:S116–22.40. Hunter R, Gordon A, McLuskie R et al. Gross regional cerebralhypofunction with normal CT scan in Creutzfeldt–Jakob disease.Lancet 1989; 333: 214–15.41. Pohl P, Vogl G, Fill H et al. Single photon emission computedtomography in AIDS dementia complex. J Nucl Med 1988; 29:1382–6.